Get started
Author

Yusuke Noda

GNRI Sustainability during One Cycle of First-Line Chemotherapy as a Prognostic Indicator in Patients with Metastatic Urothelial Carcinoma
2023 · Yosuke Sugiyama, Taku Naiki, et al. · Oncology · 8
Experience and Prognostic Analysis with Avelumab Switch Maintenance Treatment in Metastatic Urothelial Carcinoma
2024 · Teruki Isobe, Taku Naiki, et al. · Oncology · 3
Impact of Organ‐Specific Severe Immune‐Related Adverse Events on Long‐Term Survival and Treatment Transitions in Metastatic Renal Cell Carcinoma: A 5‐Year Multicenter Multistate Analysis
2026 · Yoshihiko Tasaki, Kazumasa Sato, et al. · Cancer Medicine
PDF
Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin
2026 · Kunihiro Odagiri, Toshiharu Morikawa, et al. · Cancer Medicine
PDF
Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer
2026 · Kunihiro Odagiri, Yoshihiko Tasaki, et al. · Cancer Medicine
Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up
2026 · Hiroaki Ikoma, Shuzo Hamamoto, et al. · Cancers
PDF
Impact of high relative dose intensity on effectiveness and treatment continuity of IO-TKI therapy in Japanese advanced renal cell carcinoma
2026 · Yoshihiko Tasaki, Shuzo Hamamoto, et al. · Scientific Reports
PDF
The prognostic efficacy of a sustainable geriatric nutritional risk index for avelumab switch maintenance therapy in metastatic urothelial carcinoma
2023 · Teruki Isobe, Taku Naiki, et al. · Research Square
PDF
Elevated eosinophils as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma
2022 · Yoshihiko Tasaki, Shuzo Hamamoto, et al. · Research Square
PDF
Elevated eosinophils as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma： a multicenter cohort study Eosinophil could be biomarkers for irAE
2022 · Yoshihiko Tasaki, Shuzo Hamamoto, et al. · Research Square
PDF
Works count: 10
Citation count: 11
H-index: 2
I10-index:
Year
Topic
Type